MORE ARTICLES

Stay Connected!

Receive the latest updates in your inbox.

LATEST ARTICLES

William & Mary’s Dr. Charles Hobson on Chief Justice John Marshall, SCOTUS, & Judicial Review

/in , , /by Editorial Staff

This week on “The Learning Curve,” co-hosts Cara Candal and Gerard Robinson talk with Dr. Charles Hobson, a retired resident scholar at the William & Mary Law School, 26-year editor of The Papers of John Marshall, and author of The Great Chief Justice: John Marshall and the Rule of Law. Dr. Hobson shares what students should know about the longest-serving, most important chief justice in the history of the Supreme Court, and his influence on our understanding of the U.S. Constitution.

Drug Price Control: Bad Medicine for Healthcare and Region

/in , , /by Editorial Staff

Hubwonk host Joe Selvaggi talks with Dr. Bill Smith, Director of Pioneer Institute’s Life Sciences Initiative, about the impact of the Inflation Reduction Act on long-term health costs. They discuss the bill’s unintended consequences, potential effect on the region’s vibrant pharmaceutical research and development sector, and what citizens can do about it.

Massachusetts Needs a Comprehensive Performance Management Framework

/0 Comments/in , , , , , , /by Joseph Staruski

Massachusetts tried making a performance structure, but in 2014 it was discontinued. Today, the state lacks a comprehensive structure to track progress.

The Realities Behind US Healthcare Spending

/in , , , /by Gauri Binoy

Healthcare policy is an all-encompassing term. It plays a role in every individual’s life; how it is curated, developed, and maintained has a significant long-term impact on the quality of life of any given community. It is critical that policymakers consistently adapt and amend healthcare policies in the ever-changing global pricing and affordability environment while providing funding support for optimal quality of care.

Cures for Patients, Not Health Plan Profits, Make Drugs Valuable

/in , /by William Smith

To the astonishment of many observers, the Institute for Clinical and Economic Review (ICER) recently concluded that a $2.1 million gene therapy for a life-threatening blood disorder called beta thalassemia, is priced cost-effectively. The surprise was especially pleasant, given that ICER’s methodology had, in the past, displayed bias against rare disease treatments and undervalued the lives of people living with disabilities.